Novo faces growth challenges despite GLP-1 receptor agonist obesity boom
The industry is seeking to scale up and satisfy demand for diabetes and obesity treatments that are now chronically in shortage.
The industry is seeking to scale up and satisfy demand for diabetes and obesity treatments that are now chronically in shortage.
What's Your Reaction?
